ResearchWorks Archive

Use of oral contraceptives (OC) and breast cancer risk among young women by OC formulation and breast cancer subtype

Show simple item record

dc.contributor.advisor Li, Christopher I en_US Beaber, Elisabeth Frances en_US 2012-09-13T17:22:33Z 2012-09-13 2012 en_US
dc.identifier.other Beaber_washington_0250E_10399.pdf en_US
dc.description Thesis (Ph.D.)--University of Washington, 2012 en_US
dc.description.abstract Background: Many studies suggest a modest increased breast cancer risk is associated with recent oral contraceptive (OC) use, but risks associated with contemporary OCs and molecular subtypes of breast cancer are less well known. Estrogen and progestin doses have declined and new progestins have been used since OCs were introduced. Furthermore, the vast majority of studies have relied on self-reported OC use, rather than pharmacy data. Methods: Two studies examining invasive breast cancer risk were conducted in western Washington state. The first was a population-based interview case-control study among women ages 20-44 from 2004-2010 (985 cases, 882 controls). Logistic regression was used to estimate associations between lifetime OC use, overall risk, and breast cancer risk by subtype (estrogen receptor positive (ER+), ER-, and triple-negative (ER-/PR-/HER2-)). The second study was a nested case-control study among Group Health Cooperative health plan enrollees. Cases were ages 20-49 at diagnosis from 1990-2009 (n=1102) and controls were randomly selected (n=21952). Associations between recent OC use (within 1 year of reference date) by OC formulation and ER status were evaluated using conditional logistic regression. Results: In the first study, recent OC use for ≥5 years increased breast cancer risk (odds ratio (OR)=1.6), as well as lifetime duration of use for ≥15 years (OR=1.5). There was no statistically significant risk heterogeneity by OC formulation. ORs were generally greater among women ages 20-39. ER- cancer ORs were greater than ER+ ORs. Triple-negative breast cancer ORs were especially elevated. In the second study, recent OC use increased breast cancer risk (OR=1.6). Risk was greater for ER+ (OR=1.7) than ER- cancer (OR=1.3). Risk varied by OC formulation, with some OCs associated with an increased risk and others not associated with risk. Conclusions: We found that recent use of contemporary OCs increases breast cancer risk among women ages 20-49 and that long durations of use increases risk among ages 20-44. Risks may be greater among younger women and for triple-negative breast cancer. Risks may also vary by OC formulation. Continued monitoring of breast cancer risk is essential as OC formulations and use patterns continue to evolve. en_US
dc.format.mimetype application/pdf en_US
dc.language.iso en_US en_US
dc.rights Copyright is held by the individual authors. en_US
dc.subject breast cancer; case-control study; estrogen; oral contraceptives; progestin en_US
dc.subject.other Epidemiology en_US
dc.subject.other Epidemiology en_US
dc.title Use of oral contraceptives (OC) and breast cancer risk among young women by OC formulation and breast cancer subtype en_US
dc.type Thesis en_US
dc.embargo.terms Delay release for 2 years -- then make Open Access en_US
dc.embargo.lift 2014-09-03T17:22:33Z

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ResearchWorks

Advanced Search


My Account